ANGO (AngioDynamics, Inc.) Stock | Pipeline, Insider Trades & Financials

Jul 14, 2026

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

AngioDynamics, Inc. reported record financial results for the fourth quarter and full year of fiscal year 2026, ending May 31, 2026. The company highlighted significant year-over-year growth in its medical technology sector, contributing to improved profitability. This performance underscores AngioDynamics' commitment to enhancing patient care and expanding treatment options.

Jun 30, 2026

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

AngioDynamics has announced the date for its fiscal 2026 fourth quarter and full-year financial results, which will be reported on July 14, 2026. This announcement is part of the company's regular financial reporting schedule. Investors and stakeholders are likely to monitor these results for insights into the company's financial performance.

Jun 17, 2026

ANGOFDA Updates

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

AngioDynamics has received FDA Investigational Device Exemption (IDE) approval for its RELIEF feasibility study. This study will evaluate the NanoKnife IRE platform as a minimally invasive treatment for benign prostatic hyperplasia (BPH). The approval marks a significant step in exploring new treatment options for patients suffering from BPH.

May 28, 2026

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

AngioDynamics has announced an expansion of patient access to its NanoKnife IRE technology for treating prostate and liver cancer. This initiative coincides with the implementation of a new Medicare coverage framework, which is expected to enhance treatment options for patients. The move aims to improve patient outcomes and broaden the availability of this innovative technology.

May 27, 2026

AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AngioDynamics is scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference. The event will provide a platform for the company to discuss its strategies and future directions in the healthcare sector. Details regarding the presentation's content and timing are yet to be disclosed.

May 13, 2026

ANGOPhases

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

AngioDynamics has announced data from the two-year PRESERVE trial, which evaluates the outcomes of the NanoKnife IRE system in treating intermediate-risk prostate cancer. The results indicate the system's durability and effectiveness in this patient population. Further details on the trial's findings and implications for clinical practice were not provided.

AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability

AngioDynamics has reported its financial results for the third quarter of fiscal year 2026, highlighting sustained double-digit growth in the Med Tech sector. The company continues to demonstrate profitability, reflecting its strong market position. This positive performance underscores AngioDynamics' resilience and effective business strategies.

Mar 31, 2026

AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference

AngioDynamics, Inc. will present at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 8:45 a.m. (ET). The event will be accessible via a live webcast on the company's website, which will also offer a replay afterward. This presentation underscores AngioDynamics' role in advancing medical technology and patient care.

Feb 24, 2026

AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

AngioDynamics, Inc. will present at the Leerink Partners Global Healthcare Conference on March 9, 2026. CEO Jim Clemmer will lead the presentation, which aims to showcase the company's advancements in medical technology. A live webcast will be available for those interested in the event.

Feb 5, 2026

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

AngioDynamics and The PERT Consortium have launched the ALPHA-PE Research Fund to support independent research in pulmonary embolism (PE) care. This initiative aims to address critical evidence gaps by funding investigator-led studies that focus on patient outcomes and innovative treatment approaches. Grants will range from $50,000 to $750,000, fostering collaboration within the cardiovascular community.

Feb 4, 2026

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

AngioDynamics is set to host its third Cardiovascular Scientific Forum from February 6-8, 2026, in Fort Lauderdale, Florida. The event will focus on physician-led collaboration and the advancement of cardiovascular technologies. Recent FDA approvals for the AlphaReturn Blood Management System and the AlphaVac F1885 System support ongoing clinical studies and enhance treatment options for patients with complex cardiovascular conditions.

Jan 14, 2026

J.P. Morgan 44th Annual Healthcare Conference

AngioDynamics showcased its forward-looking strategy at the J.P. Morgan 44th Annual Healthcare Conference, emphasizing its positioning for sustained growth in the MedTech space. The company highlighted its successful products, including Auryon, which has seen significant sales and usage since its launch. However, management acknowledged various risks, including competition, regulatory challenges, and ongoing litigation that could impact future performance.

Jan 6, 2026

▼ -13.5%on this news· ran to -25% by day 3

AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability Med Tech segment delivers fifth consecutive quarter of double-digit growth, S

AngioDynamics, Inc. announced its financial results for the second quarter of fiscal year 2026, reporting an 8.8% increase in net sales, driven primarily by a 13.0% growth in its Med Tech segment. The company achieved important FDA approvals for new studies and expanded product capabilities, contributing to its optimism for sustained growth. However, it recorded a GAAP net loss of $6.4 million during the quarter. The successful conclusion of a protracted litigation with C.R. Bard also bolstered the company's position as it moves forward in fiscal 2026.

Dec 24, 2025

AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026

AngioDynamics, Inc. will report its financial results for the second quarter of fiscal 2026 on January 6, 2026, before market opening. The company will host a conference call at 8:00 am ET to discuss these results. Investors can participate via phone or webcast, with a recording available afterward.

Dec 22, 2025

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

AngioDynamics, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will be led by CEO Jim Clemmer and CFO Stephen Trowbridge. A live webcast will be available on the company's website, allowing broader access to their insights and innovations.

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum Med Tech segment delivers fourth consecutive quarter of over 20% revenue growth Reported Adjusted

AngioDynamics reported its financial results for the first quarter of fiscal year 2026, highlighting a 26.1% growth in the Med Tech segment. This marks the fourth consecutive quarter with over 20% revenue growth, driven by strong performance from key products like Auryon and AlphaVac. Despite the overall net sales of $75.7 million representing a 12.2% increase, the company also reported a net loss of $10.9 million. Additionally, significant clinical milestones were achieved with the enrollment of the first patients in multiple key clinical trials.

AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth Med Tech franchise delivers third consecutive quarter of over 20% r

AngioDynamics, Inc. reported strong financial results for the fourth quarter and full fiscal year 2025, highlighted by a 22% growth in Med Tech net sales. The company experienced over 20% revenue growth for the third consecutive quarter, achieving significant free cash flow and positive adjusted EBITDA. Despite these successes, AngioDynamics faced a GAAP net loss and challenges related to tariffs impacting gross margins. The firm's strategic transformation and focus on growth in large market opportunities have positioned it well for the future.

Apr 2, 2025

▲ +12.4%on this news

INVESTOR EVENT Shaping the Future of Cardiovascular Care: Innovative Technologies. Improved Outcomes. Forward Looking Statements Forward Looking Statements Notice Regarding Forward-Looking Statements This presentation co

AngioDynamics is hosting an investor event focused on future advancements in cardiovascular care through innovative technologies. The company is set to expand its product offerings while emphasizing the importance of clinical and regulatory strategies. Notably, the Auryon system is expected to drive significant revenue growth. However, the firm acknowledges risks associated with market competition and regulatory hurdles as it aims to enhance patient outcomes.

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results LATHAM, N.Y.--(BUSINESS WIRE)

AngioDynamics reported its financial results for the third quarter of fiscal year 2025, showing a 9.2% increase in net sales to $72.0 million compared to the previous year. The Med Tech segment experienced robust growth at 22.2%, driven by products like Auryon and AngioVac. The company has received FDA clearance for its innovative NanoKnife System for prostate treatment and initiated a key clinical trial for critical limb ischemia. Despite a non-GAAP net loss of $3.1 million, AngioDynamics is optimistic about achieving positive operating cash flow in the upcoming quarter.

Jan 16, 2025

J.P. Morgan 43rd Annual Healthcare Conference

AngioDynamics presented its strategic outlook at the J.P. Morgan 43rd Annual Healthcare Conference, emphasizing the strength of its Med Tech segment, which is expected to drive a significant portion of revenue. The company projects positive adjusted EBITDA by FY2025 and highlights its innovative product pipeline aimed at addressing major health issues such as cardiovascular disease and cancer. Key market dynamics indicate potential for sustained growth despite existing risks related to competition, regulatory environments, and economic conditions. AngioDynamics maintains a strong balance sheet, reinforcing its position in the medical technology industry.

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results LATHAM, N.Y.--(BUSINESS WIRE)

AngioDynamics, Inc. reported its financial results for the second quarter of fiscal year 2025, highlighting a 9.2% increase in pro forma net sales, totaling $73.0 million. The Med Tech segment experienced a notable 25% growth compared to the previous year, driven by strong sales across key products including the Auryon and NanoKnife systems. Despite these gains, the company reported a net loss of $10.7 million and experienced a slight decline in Med Device net sales. The NanoKnife System achieved significant regulatory milestones, including CPT Category I codes and FDA clearance for prostate tissue ablation, positioning it for accelerated market growth.

Edit Title 1 2 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding Angi

AngioDynamics has made significant strides by broadening its Med Tech portfolio through research and development, as well as mergers and acquisitions. The company is entering various high-potential markets, including mechanical thrombectomy and prostate care, which are expected to contribute to future growth. Additionally, AngioDynamics is focused on enhancing its R&D pipeline while reallocating resources from non-strategic businesses to strengthen its financial profile. The company's FDA-cleared technology for treating prostate tissue signifies a commitment to innovation and improving patient outcomes.

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results LATHAM, N.Y.--(BUSINESS WIRE)

AngioDynamics, Inc. reported its first quarter financial results for fiscal 2025, ending August 31, 2024, showing net sales of $67.5 million, which represents a slight increase of 1.1% year-over-year. The Med Tech segment performed well, with notable growth from Auryon and AlphaVac, while the Med Device segment experienced a decline in sales. The company recorded a net loss of $12.8 million and saw a significant decrease in international net sales. Additionally, AngioDynamics received CE Mark approval for its Auryon System, enabling expansion into the European market.

ANGIODYNAMICS, INC. AND SUBSIDIARIES PRO FORMA CONSOLIDATED INCOME STATEMENTS (in thousands, except per share data) Three Months Ended Three Months Ended As Reported (1) Pro Forma Adjustments (2) Pro Forma As Reported (1

AngioDynamics, Inc. reported a pro forma net loss of $2,730,000 for the three months ending August 31, 2023, showing a significant decline from a loss of $18,140,000 in the same period last year. Revenue for this period was reported at $78,679,000, a decrease from $81,537,000 in the prior year. The company's gross profit margin also slipped to 50.9% from 51.9%. The financial statements reflect adjustments related to the discontinuation and sale of certain businesses, impacting overall sales and operational metrics.

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results LATHAM, N.Y.--(B

AngioDynamics, Inc. reported their financial results for the fourth quarter and full-year fiscal 2024, ending on May 31, 2024. The company experienced a 1.9% increase in net sales for the fourth quarter, with the Med Tech segment showing an 11.3% growth. However, the Med Device segment saw a decline of 3.8%. The company faced a significant GAAP net loss attributed to impairment charges, even as it anticipates future growth through product expansions and a stock repurchase program.

Apr 4, 2024

▲ +5.3%on this news· ran to +16% by day 1

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guida

AngioDynamics, Inc. reported its third quarter financial results for fiscal year 2024, showing net sales of $66.0 million, an 8.0% increase compared to the prior year. The company achieved significant growth from its Med Tech and Med Device portfolios and received FDA clearance for its AlphaVac device. However, it also faced a GAAP net loss of $190.4 million due to a goodwill impairment charge, among other costs. The divestiture of certain assets aims to strengthen the company's balance sheet and streamline operations.

Jan 11, 2024

J.P. Morgan Healthcare Conference

At the J.P. Morgan Healthcare Conference on January 11, 2024, AngioDynamics highlighted its commitment to investing in innovative medical technologies to address significant treatment gaps. The company reported strong past performance with its Auryon Atherectomy System and announced a robust pipeline of upcoming product launches and clinical studies. However, several technologies remain unapproved by the FDA for certain indications, introducing potential regulatory challenges. AngioDynamics aims to enhance its market presence through strategic investments and international expansion.

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guid

AngioDynamics, Inc. reported its second quarter financial results for fiscal year 2024, revealing a net sales increase of 2.7% year-over-year. Despite the rise in overall sales, the company faced a net loss of $29 million primarily due to challenges in the Thrombus business. AngioDynamics is transitioning to an outsourced manufacturing model, which is expected to drive significant cost reductions and help achieve profitability by FY27. The company has also completed enrollment in its APEX-AV trial, indicating potential future growth avenues.

Oct 4, 2023

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Gui

AngioDynamics, Inc. reported its fiscal year 2024 first quarter financial results, revealing net sales of $78.7 million, a 5.7% increase when excluding certain product sales. Med Tech sales rose 13.3%, driven by a significant demand for the Auryon platform and NanoKnife technology. Despite positive growth indicators, the company noted a decline in AngioVac sales and reported an adjusted net loss of $4.8 million for the quarter. The company reaffirmed its fiscal year 2024 guidance, projecting net sales between $328 to $333 million.

Jul 24, 2023

Stephen Trowbridge Saleem Cheeks 518-795-1408 518-795-1174 strowbridge@angiodynamics.com scheeks@angiodynamics.com AngioDynamics Announces Addition of Lorinda Burg

AngioDynamics, Inc. has announced the appointment of Lorinda Burgess to its Board of Directors. Ms. Burgess, who has over 35 years of experience in management and finance, previously served as CFO for the Americas Region at Medtronic. Her extensive background in optimizing operational efficiencies is expected to contribute significantly to AngioDynamics' strategic growth initiatives. The addition of Ms. Burgess increases the board's total members to nine.

Jul 12, 2023

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2023 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Y

AngioDynamics, Inc. reported its financial results for the fourth quarter and full fiscal year 2023, ending May 31, 2023. While net sales showed an increase, the company faced a net loss of $21.5 million for the quarter, largely affected by a goodwill impairment linked to recent divestitures. Looking ahead, the management is positive about future growth and plans to focus more on its high-growth Med Tech platforms.

Jun 14, 2023

AngioDynamics, Inc. Unaudited Pro Forma Condensed Consolidated Financial Statements AngioDynamics, Inc. and Subsidiaries UNAUDITED PRO FORMA CONSOLIDATED STATEMENTS OF OPERATIONS Nine Months Ended

AngioDynamics, Inc. has released its unaudited pro forma condensed consolidated financial statements for the nine months ended February 28, 2023, demonstrating a net loss of $43.67 million. The pro forma adjustments reveal that net sales have declined significantly due to the elimination of revenues from a business sale. Both operating losses and overall financial performance have shown deterioration across the reported periods, highlighting challenges ahead for the company.

Jun 8, 2023

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Announces Sale of Dialysis Product Portfolio and BioSentry Product to Merit Medical Syst

AngioDynamics, Inc. has announced the completion of its sale of the Dialysis product portfolio and BioSentry product to Merit Medical Systems for $100 million. This deal is part of AngioDynamics' strategy to focus on high-growth Med Tech platforms and is expected to enhance their balance sheet. The sale is projected to be slightly dilutive to corporate gross margins and adjusted earnings per share. Management anticipates net sales for the recently completed fiscal year to range between $338 million to $339 million.

Apr 17, 2023

Needham & Company 22nd Annual Virtual Healthcare Conference

AngioDynamics presented at the Needham & Company 22nd Annual Virtual Healthcare Conference, discussing its forward-looking approach to product development and market positioning. The company highlighted key technologies like the NanoKnife System, which has received necessary regulatory clearances for surgical applications. However, management underscored the various risks associated with future performance, including competitive pressures and regulatory challenges that may affect product approvals. Overall, the conference aimed to showcase AngioDynamics' strategic focus on high-growth medical technology markets.

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2023 Third Quarter Financial Results; Revises Guidance Fiscal Year 2023 T

AngioDynamics, Inc. announced its financial results for the third quarter of fiscal 2023, revealing a net sales increase of 9.1% to $80.7 million. Despite this, the company faced a net loss of $9.5 million, which was larger than the previous year’s loss. AngioVac sales have declined by 15.7%, prompting a revision in fiscal year guidance, with projected net sales now expected between $338 million to $342 million. Gains in Med Tech sales were seen, primarily driven by Auryon and NanoKnife products, although gross margins have been negatively impacted by inflation.

Mar 6, 2023

▼ -7.2%on this news

Raymond James 44th Annual Institutional Investors Conference

AngioDynamics presented at the Raymond James 44th Annual Institutional Investors Conference, highlighting its focus on significant growth markets and its technological advancements aimed at improving patients' quality of life. The company discussed its current product offerings and strategic initiatives, while also acknowledging the risks associated with forward-looking statements and competition in the medical device sector. Key areas of focus include the development of the NanoKnife System and advancements in peripheral artery and thrombectomy treatments. The presentation underscored the importance of regulatory approvals and market acceptance for success.

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2023 Second Quarter Financial Results; Reaffirms Guidance Fiscal Year 202

AngioDynamics, Inc. reported second quarter financial results for fiscal 2023, highlighting a 9.1% increase in net sales compared to the prior year, driven by strong performance in its Med Tech segment. Despite these positive results, the company experienced a net loss of $8.5 million during the quarter. Management reaffirmed its fiscal year guidance, expecting net sales in the range of $342 to $348 million, while also acknowledging the challenges posed by increased operational costs. The company continues to make progress in expanding treatment options for prostate cancer patients through its Preserve study.

Nov 30, 2022

2022 ANGIODYNAMICS Piper Sandler Healthcare Conference Jim Clemmer, President & CEO Stephen Trowbridge, Executive VP & CFO 1 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking s

11 | 30 | 2022 ANGIODYNAMICS Piper Sandler Healthcare Conference Jim Clemmer, President & CEO Stephen Trowbridge, Executive VP & CFO 1 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securiti

Oct 6, 2022

▼ -19.5%on this news· ran to -38% by day 3

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2023 First Quarter Financial Results; Reaffirms Guidance Fiscal Year 2023

Stephen Trowbridge, Executive Vice President & CFO AngioDynamics Reports Fiscal 2023 First Quarter Financial Results; Reaffirms Guidance Fiscal Year 2023 First Quarter Highlights Latham, New York, October 6, 2022 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transforma

Aug 10, 2022

2022 ANGIODYNAMICS Canaccord Growth Conference Stephen Trowbridge, EVP & CFO 1 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Se

08 | 10 | 2022 ANGIODYNAMICS Canaccord Growth Conference Stephen Trowbridge, EVP & CFO 1 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statement

Jul 12, 2022

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal Year 2022 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Y

Stephen Trowbridge, Executive Vice President & CFO AngioDynamics Reports Fiscal Year 2022 Fourth Quarter and Full-Year Financial Results; Issues Fiscal Year 2023 Guidance Fiscal Year 2022 Fourth Quarter Highlights Full-Year 2022 Highlights Latham, New York, July 12, 2022 -

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2022 Third Quarter Financial Results; Reaffirms Fiscal Year 2022 Guidance

Stephen Trowbridge, Executive Vice President & CFO AngioDynamics Reports Fiscal 2022 Third Quarter Financial Results; Reaffirms Fiscal Year 2022 Guidance Fiscal 2022 Third Quarter Highlights Latham, New York, April 7, 2022 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading and

Jan 10, 2022

2022 ANGIODYNAMICS Needham Healthcare ConferenceJim Clemmer, President & CEO Stephen Trowbridge, EVP & CFO 1 2 Notice Regarding Forward-Looking StatementsThis presentation containsforward-looking statementswithin th

01 | 10 | 2022 ANGIODYNAMICS Needham Healthcare ConferenceJim Clemmer, President & CEO Stephen Trowbridge, EVP & CFO 1 2 Notice Regarding Forward-Looking StatementsThis presentation containsforward-looking statementswithin the meaning of the Private Securities Litigation Refor

Jan 6, 2022

▼ -11.8%on this newsshared move

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revise

Stephen Trowbridge, Executive Vice President & CFO AngioDynamics Reports Fiscal 2022 Second Quarter Financial Results; Reaffirms Revenue Guidance; Revises Gross Margin and Adjusted EPS Guidance Fiscal 2022 Second Quarter Highlights Latham, New York, January 6, 2022 - AngioDy

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance Fiscal 2022 First

Stephen Trowbridge, Executive Vice President & CFO AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Fiscal 2022 First Quarter Highlights Latham, New York, September 30, 2021 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally in

Jul 13, 2021

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results Fiscal 2021 Fourth Qu

Stephen Trowbridge, Executive Vice President & CFO AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results Fiscal 2021 Fourth Quarter Highlights Full-Year 2021 Highlights Latham, New York, July 13, 2021 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading

Jul 13, 2021

Investor & technology day JULY 2021 AGENDA 9:30 - 10:50 AM ET | BUSINESS PRESENTATIONS ANGIODYNAMICS OVERVIEW GROWTH STRATEGY & TECHNOLOGY OVERVIEW KEY TECHNOLOGY PLATFORM OVERVIEW Thrombus management - ANGIOVAC & ALPHAV

1 Investor & technology day JULY 2021 AGENDA 9:30 - 10:50 AM ET | BUSINESS PRESENTATIONS ANGIODYNAMICS OVERVIEW GROWTH STRATEGY & TECHNOLOGY OVERVIEW KEY TECHNOLOGY PLATFORM OVERVIEW Thrombus management - ANGIOVAC & ALPHAVAC PERIPHERAL ATHERECTOMY - AURYON IRREVERSIBLE ELECTROP

May 25, 2021

2021 ANGIODYNAMICS The UBS 2021 Virtual Global Healthcare Conference Jim Clemmer, President & CEO 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking sta

05 | 25 | 2021 ANGIODYNAMICS The UBS 2021 Virtual Global Healthcare Conference Jim Clemmer, President 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litiga

Apr 12, 2021

2021 ANGIODYNAMICS The 20th Annual Needham Virtual Healthcare ConferenceJim Clemmer, President & CEOStephen Trowbridge, EVP & CFO 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis pres

04 | 12 - 15 | 2021 ANGIODYNAMICS The 20th Annual Needham Virtual Healthcare ConferenceJim Clemmer, President & CEOStephen Trowbridge, EVP & CFO 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within

Mar 30, 2021

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2021 Third Quarter Financial Results and Updates Guidance Fiscal 2021 Thi

Stephen Trowbridge, Executive Vice President & CFO AngioDynamics Reports Fiscal 2021 Third Quarter Financial Results and Updates Guidance Fiscal 2021 Third Quarter Highlights Latham, New York, March 30, 2021 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovati

Mar 9, 2021

2021 ANGIODYNAMICS Barclays Global Healthcare ConferenceJim Clemmer, President & CEOStephen Trowbridge, EVP & CFO 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains for

03 | 09 | 2021 ANGIODYNAMICS Barclays Global Healthcare ConferenceJim Clemmer, President & CEOStephen Trowbridge, EVP & CFO 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Pr

Jan 11, 2021

2021 ANGIODYNAMICS 23rd Annual Needham Virtual Growth Conference Jim Clemmer, President & CEO 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking stateme

01 | 11 | 2021 ANGIODYNAMICS 23rd Annual Needham Virtual Growth Conference Jim Clemmer, President & 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigati

Jan 7, 2021

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2021 Second Quarter Financial Results Fiscal 2021 Second Quarter Highligh

Stephen Trowbridge, Executive Vice President & CFO AngioDynamics Reports Fiscal 2021 Second Quarter Financial Results Fiscal 2021 Second Quarter Highlights Latham, New York, January 7, 2021 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally inva

Jan 7, 2021

ANGIODYNAMICS Second Quarter 2021 Earnings Presentation

ANGIODYNAMICS Second Quarter 2021 Earnings PresentationJanuary 7, 2021 1 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All

Nov 19, 2020

2020 ANGIODYNAMICS Canaccord Genuity2020 Medical Technologies & Diagnostics Forum 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within t

11 | 19 | 2020 ANGIODYNAMICS Canaccord Genuity2020 Medical Technologies & Diagnostics Forum 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Refor

Sep 29, 2020

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2021 First Quarter Financial Results Fiscal 2021 First Quarter Highlights

Stephen Trowbridge, Executive Vice President & CFO AngioDynamics Reports Fiscal 2021 First Quarter Fiscal 2021 First Quarter Highlights Latham, New York, September 29, 2020 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical dev

Jul 16, 2020

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2020 Fourth Quarter and Full-Year Financial Results Fiscal 2020 Fourth Qu

Stephen Trowbridge, Executive Vice President & CFO AngioDynamics Reports Fiscal 2020 Fourth Quarter and Full-Year Financial Results Fiscal 2020 Fourth Quarter Highlights Full-Year 2020 Highlights Latham, New York, July 16, 2020 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading

Apr 7, 2020

Investor Contact: AngioDynamics, Inc. Stephen Trowbridge, Executive Vice President & CFO (518) 795-1408 AngioDynamics Reports Fiscal 2020 Third Quarter Financial Results Fiscal 2020 Third Quarter Highlights

Stephen Trowbridge, Executive Vice President & CFO AngioDynamics Reports Fiscal 2020 Third Quarter Financial Results Fiscal 2020 Third Quarter Highlights Latham, New York, April 7, 2020 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive

Feb 6, 2020

AngioDynamics, Inc. Stephen Trowbridge 518-795-1408 strowbridge@angiodynamics.com AngioDynamics, Inc. Saleem Cheeks 518-795-1174 scheeks@angiodynamics.com AngioDyna

Investor Relations Contact: Media Contact: AngioDynamics, Inc. Stephen Trowbridge 518-795-1408 strowbridge@angiodynamics.com AngioDynamics, Inc. Saleem Cheeks 518-795-1174 scheeks@angiodynamics.com AngioDynamics Appoints Stephen Trowbridge Executive Vice President and Chief Fina

Jan 16, 2020

J.P.

J.P. MORGAN HEALTHCARE CONFERENCEAngioDynamicsJim Clemmer, President and CEOJanuary 16, 2020 Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statemen

Oct 3, 2019

Investor Contact: AngioDynamics, Inc. Michael C. Greiner, Executive Vice President & CFO (518) 795-1821 AngioDynamics Reports Fiscal 2020 First Quarter Financial Results Fiscal 2020 First Quarter Highlights

Michael C. Greiner, Executive Vice President & CFO AngioDynamics Reports Fiscal 2020 First Quarter Financial Results Fiscal 2020 First Quarter Highlights Latham, New York, October 3, 2019 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasiv

Sep 27, 2018

Investor Contact: AngioDynamics, Inc. Michael C. Greiner, Executive Vice President & CFO (518) 795-1821 AngioDynamics Reports Fiscal 2019 First Quarter Financial Results Fiscal 2019 First Quarter Highlights

Michael C. Greiner, Executive Vice President & CFO AngioDynamics Reports Fiscal 2019 First Quarter Financial Results Fiscal 2019 First Quarter Highlights Latham, New York, September 27, 2018 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally inva

Sep 27, 2018

AngioDynamics First Quarter 2019 Earnings Presentation

AngioDynamics First Quarter 2019 Earnings PresentationSeptember 27, 2018 2 Forward-Looking Statements Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All

Sep 6, 2018

Wells Fargo Securities Healthcare Conference

Wells Fargo Securities Healthcare Conference September 6, 2018 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regardi

Jul 11, 2018

PRESENTATION DATED JULY 11, 2018 AngioDynamics Fourth Quarter 2018 Earnings Presentation

AngioDynamics Fourth Quarter 2018 Earnings PresentationJuly 11, 2018 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All state

Jul 11, 2018

Investor Contact: AngioDynamics, Inc. Michael C. Greiner, Executive Vice President & CFO (518) 795-1821 AngioDynamics Reports Fiscal 2018 Fourth Quarter and Full-Year Financial Results Fiscal 2018 Fourth Qu

Michael C. Greiner, Executive Vice President & CFO AngioDynamics Reports Fiscal 2018 Fourth Quarter and Full-Year Financial Results Fiscal 2018 Fourth Quarter Highlights Full-Year 2018 Highlights Latham, New York, July 11, 2018 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading

Mar 29, 2018

AngioDynamics Third Quarter 2018 Earnings PresentationMarch 29, 2018

AngioDynamics Third Quarter 2018 Earnings PresentationMarch 29, 2018 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All state

Mar 29, 2018

Investor Contact: AngioDynamics, Inc. Michael C. Greiner, Executive Vice President & CFO (518) 795-1821 AngioDynamics Reports Fiscal 2018 Third Quarter Financial Results Fiscal 2018 Third Quarter Highlights

Michael C. Greiner, Executive Vice President & CFO AngioDynamics Reports Fiscal 2018 Third Quarter Financial Results Fiscal 2018 Third Quarter Highlights Latham, New York, March 29, 2018 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive

Jan 24, 2018

ANGOFDA Updates

Investor Contact: AngioDynamics, Inc. Michael Greiner, Executive Vice President & CFO (518) 795-1821 AngioDynamics Receives FDA Expedited Access Pathway Designation for the NanoKnife System for the Treatmen

Michael Greiner, Executive Vice President & CFO AngioDynamics Receives FDA Expedited Access Pathway Designation for the NanoKnife System for the Treatment of Stage III Pancreatic Cancer Latham, New York, January 24, 2018 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading provide

Jan 10, 2018

J.P. Morgan Healthcare Conference - AngioDynamics Investor Presentation

J.P. Morgan Healthcare Conference - AngioDynamics Investor Presentation January 10, 2018 Forward-Looking Statement Notice Regarding Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 19

Jan 4, 2018

Investor Contact: AngioDynamics, Inc. Michael Greiner, Executive Vice President & CFO (518) 795-1821 AngioDynamics Reports Fiscal 2018 Second Quarter Financial Results Fiscal 2018 Second Quarter Highlights

Michael Greiner, Executive Vice President & CFO AngioDynamics Reports Fiscal 2018 Second Quarter Financial Results Fiscal 2018 Second Quarter Highlights Latham, New York, January 4, 2018 - AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive

Jan 4, 2018

AngioDynamics Second Quarter 2018 Earnings PresentationJanuary 4th, 2018 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of

AngioDynamics Second Quarter 2018 Earnings PresentationJanuary 4th, 2018 2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All s

Sep 28, 2017

AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 cstefanik@angiodynamics.com FTI Consulting Jim Polson (312) 553-6730 Jim.Polson@f

FOR IMMEDIATE DISTRIBUTION Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 cstefanik@angiodynamics.com FTI Consulting Jim Polson (312) 553-6730 Jim.Polson@fticonsulting.com , Kotaro Yoshida (212) 850-5690 Kotaro.Yos

Aug 4, 2017

ANGIODYNAMICS, INC. AND SUBSIDIARIES CONSOLIDATED INCOME STATEMENTS (in thousands, except per share data) Three months ended Twelve months ended May 31, May 31, May 31

ANGIODYNAMICS, INC. AND SUBSIDIARIES CONSOLIDATED INCOME STATEMENTS (in thousands, except per share data) Three months ended Twelve months ended May 31, May 31, May 31, May 31, 2017 2016 2017 2016 (unaudited) (unaudited) Net sales $ 86,914 $ 93,4

Jul 18, 2017

AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 cstefanik@angiodynamics.com FTI Consulting Jim Polson (312) 553-6730 Jim.Polson@fticon

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 cstefanik@angiodynamics.com FTI Consulting Jim Polson (312) 553-6730 Jim.Polson@fticonsulting.com , Kotaro Yoshida (212) 850-5690 Kotaro.Yoshida@fticonsulting.com FTI C

Jan 10, 2017

J.P. Morgan Healthcare ConferenceJim Clemmer, CEOMichael Greiner, CFO

J.P. Morgan Healthcare ConferenceJim Clemmer, CEOMichael Greiner, CFOJanuary 10, 2017 Forward-Looking Statement Notice Regarding Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Jan 6, 2017

AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 cstafanik@angiodynamics.com FTI Consulting Jim Polson (312) 553-6730 Jim.Polson@fticon

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 cstafanik@angiodynamics.com FTI Consulting Jim Polson (312) 553-6730 Jim.Polson@fticonsulting.com , Kotaro Yoshida (212) 850-5690 Kotaro.Yoshida@fticonsulting.com FTI C

Nov 9, 2016

AngioDynamics Announces New Senior Credit Facilities and New Share Repurchase Program New Senior Credit Facility Includes a $100 Million TLA and a $150 Million RCF Board of Directors Authorizes

FOR IMMEDIATE DISTRIBUTION AngioDynamics Announces New Senior Credit Facilities and New Share Repurchase Program New Senior Credit Facility Includes a $100 Million TLA and a $150 Million RCF Board of Directors Authorizes Up to $25 Million in Share Repurchases ALBANY, N.Y., No

Jul 25, 2016

AngioDynamics Appoints Michael C. Greiner as New Chief Financial Officer Greiner brings more than 20 years of accounting, corporate finance and operations experience from a variety of global corporations ALBANY, N.Y.

AngioDynamics Appoints Michael C. Greiner as New Chief Financial Officer Greiner brings more than 20 years of accounting, corporate finance and operations experience from a variety of global corporations ALBANY, N.Y., July 25, 2016 -- AngioDynamics (NASDAQ:ANGO), a leading prov

Apr 4, 2016

AngioDynamics Appoints James C. Clemmer as New President and Chief Executive Officer Clemmer brings more than 25 years of operational, manufacturing, marketing and business development experience in the global healthcare

AngioDynamics Appoints James C. Clemmer as New President and Chief Executive Officer Clemmer brings more than 25 years of operational, manufacturing, marketing and business development experience in the global healthcare industry ALBANY, N.Y., April 4, 2016 -- AngioDynamics (NA

Jan 7, 2016

AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 cstefanik@angiodynamics.com EVC Group, Inc. Doug Sherk; Chris Dailey (646) 445-4801 ds

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics Inc. Caitlin Stefanik (518) 795-1418 cstefanik@angiodynamics.com EVC Group, Inc. Doug Sherk; Chris Dailey (646) 445-4801 dsherk@evcgroup.com cdailey@evcgroup.com EVC Group, Inc. Dave Schemelia (646) 201-

Nov 9, 2015

AngioDynamics Inc. Caitlin Stefanik (518) 795 - 1400 x 1418 cstefanik@AngioDynamics.com EVC Group, Inc. Doug Sherk; Chris Dailey (646) 44

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics Inc. Caitlin Stefanik (518) 795 - 1400 x 1418 cstefanik@AngioDynamics.com EVC Group, Inc. Doug Sherk; Chris Dailey (646) 445-4801 dsherk@evcgroup.com; cdailey@evcgroup.com ; EVC Group, Inc. Dave Schemeli

Oct 14, 2015

Q1 FY2016 Financial Results Presentation

Q1 FY2016 Financial Results PresentationOctober 14, 2015 Forward-Looking Statements Notice Regarding Forward Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regardi

Oct 8, 2015

AngioDynamics Inc. Mark Frost, CFO (800) 772-6446 x 1981 mfrost@AngioDynamics.com EVC Group, Inc. Doug Sherk; Chris Dailey (646) 445

FOR IMMEDIATE DISTRIBUTION Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics Inc. Mark Frost, CFO (800) 772-6446 x 1981 mfrost@AngioDynamics.com EVC Group, Inc. Doug Sherk; Chris Dailey (646) 445-4801 dsherk@evcgroup.com.; cdailey@evcgroup.com; EVC Group

Aug 5, 2015

UBS 2015 SMID Cap One-on-One Conference Mark Frost, Executive Vice President & CFO

UBS 2015 SMID Cap One-on-One Conference Mark Frost, Executive Vice President & CFOAugust 5, 2015 Forward-Looking Statements Notice Regarding Forward Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Re

Jul 17, 2015

AngioDynamics Reports Fiscal 2015 Fourth Quarter and Full Year Financial Results

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics Inc. Mark Frost, CFO (800) 772-6446 x 1981 mfrost@AngioDynamics.com EVC Group, Inc. Doug Sherk; Chris Dailey (646) 445-4801 dsherk@evcgroup.com .; cdailey@evcgroup.com ; EVC Group, Inc. Dave Schemelia (646

Apr 14, 2015

Needham & Company 14 th Annual Healthcare Conference Joseph M. DeVivo, President & CEO Mark Frost, Executive Vice President & CFO

Needham & Company 14 th Annual Healthcare Conference Joseph M. DeVivo, President & CEO Mark Frost, Executive Vice President & CFO April 14, 2015 Forward - Looking Statements Notice Regarding Forward Looking Statements This presentation contains forward - looking statements withi

Apr 9, 2015

AngioDynamics Inc. Mark Frost, CFO (800) 772-6446 x1981 mfrost@AngioDynamics.com EVC Group, Inc. Chris Dailey/Robert Jones (646) 445-4801

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics Inc. Mark Frost, CFO (800) 772-6446 x1981 mfrost@AngioDynamics.com EVC Group, Inc. Chris Dailey/Robert Jones (646) 445-4801; (646) 201-5447 cdailey@evcgroup.com ; bjones@evcgroup.com EVC Group, Inc. Dave S

Nov 18, 2014

November 2014 Joseph M. DeVivo, President & CEO Mark Frost, Executive Vice President & CFO Forward-Looking Statements Notice Regarding Forward Looking Statements This presentation contains forward-looking statements with

November 2014 Joseph M. DeVivo, President & CEO Mark Frost, Executive Vice President & CFO Forward-Looking Statements Notice Regarding Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform

Nov 14, 2014

ANGIODYNAMICS, INC. AND SUBSIDIARIES CONSOLIDATED INCOME STATEMENTS As Revised (1) (in thousands, except per share data) Three months ended Year ended Three months ended Three months ended Three months ended Three months

ANGIODYNAMICS, INC. AND SUBSIDIARIES CONSOLIDATED INCOME STATEMENTS (in thousands, except per share data) Three months ended Year ended Three months ended Three months ended Three months ended Three months ended Year ended Aug 31, May 31, May 31, Feb 28,

Oct 9, 2014

AngioDynamics Inc. Mark Frost, CFO (800) 772-6446 x1981 mfrost@AngioDynamics.com EVC Group, Inc. Michael Polyviou/Robert Jones (212) 850-

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics Inc. Mark Frost, CFO (800) 772-6446 x1981 mfrost@AngioDynamics.com EVC Group, Inc. Michael Polyviou/Robert Jones (212) 850-6020; (646) 201-5447 mpolyviou@evcgroup.com ; bjones@evcgroup.com EVC Group, Inc.

Aug 14, 2014

PRESENTATION SLIDES an31248225-ex99_1.htm Joseph M. DeVivo, President and CEO August 2014 AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDy

Forward-Looking Statements Notice Regarding Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, res

Jan 15, 2014

Joseph M. DeVivo, President and CEO January 2014 AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. Copyright 2012 AngioDynamics

Aug 14, 2013

Mark Frost, Executive Vice President and CFO August 2013 AngioDynamics, the AngioDynamics logo and other trademarks displayed In this presentation are trademarks owned and used by AngioDynamics, Inc. Copyright 2012 Angio

* FORWARD-LOOKING STATEMENTS Notice Regarding Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, r

May 21, 2013

PRESENTATION SLIDES FOR THE UBS GLOBAL HEALTHCARE CONFERENCE an20130521-ex99_1.htm Joseph DeVivo, President and CEO Mark Frost, EVP and CFO May 2013 AngioDynamics, the AngioDynamics logo and other trademarks displayed in

Apr 8, 2013

AngioDynamics Inc. Mark Frost, CFO (800) 772-6446 x1981 mfrost@AngioDynamics.com EVC Group, Inc. Greg

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics Inc. Mark Frost, CFO (800) 772-6446 x1981 mfrost@AngioDynamics.com EVC Group, Inc. Greg Gin/Robert Jones (646) 445-4801; (646) 201-5447 ggin@evcgroup.com ; bjones@evcgroup.com EVC Group, Inc. Chris Gale (6

Mar 8, 2013

AngioDynamics, Inc. Mark Frost, CFO (800) 772-6446 x1981 mfrost@AngioDynamics.com EVC Group, Inc. Greg Gin/Robert Jones (646) 445-4801; (646) 201-5447 ggin@evc

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics, Inc. Mark Frost, CFO (800) 772-6446 x1981 mfrost@AngioDynamics.com EVC Group, Inc. Greg Gin/Robert Jones (646) 445-4801; (646) 201-5447 ggin@evcgroup.com ; bjones@evcgroup.com EVC Group, Inc. Chris Gale (

Jan 23, 2013

AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. Copyright 2012 AngioDynamics, Inc. All rights reserved. FY 2013 Investor & An

Agenda Topic Presenter Strategic Overview Joseph DeVivo, President & CEO Peripheral Vascular John Soto, SVP & Global Business Leader Vascular Access Chuck Greiner, SVP & Global Business Leader Oncology /Surgery Rick Stark, SVP & Global Business Leader Break Financial Overview Mar

Dec 17, 2012

DRAFT v5 Investor Relations Contacts: Media Contact: EVC Group, Inc. Jamar Ismail/Robert Jones (415) 568-9348; (646) 201-5447 jismail@evcgroup.com ; bjones@evcgroup.com EVC Group, Inc. Amy Phillips (412) 327 - 9499 aphil

Investor Relations Contacts: Media Contact: EVC Group, Inc. Jamar Ismail/Robert Jones (415) 568-9348; (646) 201-5447 jismail@evcgroup.com ; bjones@evcgroup.com EVC Group, Inc. Amy Phillips (412) 327 - 9499 aphillips@evcgroup.com AngioDynamics Appoints George Bourne Chief Technol

Nov 19, 2012

EVC Group, Inc. Jamar Ismail/Robert Jones (415) 568-9348; (646) 201-5447 jismail@evcgroup.com ; bjones@evcgroup.com EVC Group, Inc. Chris Gale (646) 201-5

Investor Relations Contacts: Media Contact: EVC Group, Inc. Jamar Ismail/Robert Jones (415) 568-9348; (646) 201-5447 jismail@evcgroup.com ; bjones@evcgroup.com EVC Group, Inc. Chris Gale (646) 201-5431 cgale@evcgroup.com Joseph Gersuk to Retire from AngioDynamics; Mark T. Frost

Oct 25, 2012

Summary Description of the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan (as amended) The following is a summary of the principal provisions of the AngioDynamics., Inc. 2004 Stock and Incentive Award Plan, as a

Summary Description of the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan (as amended) The following is a summary of the principal provisions of the AngioDynamics., Inc. 2004 Stock and Incentive Award Plan, as amended (the " 2004 Plan"). This summary is qualified in its

Oct 8, 2012

AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com EVC Group, I

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com EVC Group, Inc. Jamar Ismail/Robert Jones (415) 568-9348; (646) 201-5447 jismail@evcgroup.com ; bjones@evcgroup.com EVC Group, Inc

Jul 12, 2012

AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com EVC Group, Inc. Jamar Ismail/Robert Jones (415)

May 22, 2012

AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com EVC Group, Inc. Greg Gin/Robert Jones (646) 445-

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com EVC Group, Inc. Greg Gin/Robert Jones (646) 445-4801; (646) 201-5447 ggin@evcgroup.com ; bjones@evcgroup.com EVC Group, Inc. Chris

Apr 4, 2012

AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com EVC Group, Inc. Bob Jones/ Greg Gin (646) 201 -

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com EVC Group, Inc. Bob Jones/ Greg Gin (646) 201 - 5447/ (646) 445-4801 bjones@evcgroup.com; ggin@evcgroup.com Doug Sherk (415) 652-9

Jan 31, 2012

Acquisition of Navilyst Medical Investor Conference Call |

Acquisition of Navilyst Medical Investor Conference Call | January 31, 2012 Forward-Looking Statements This document includes "forward-looking statements" intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995

Jan 25, 2012

AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com EVC Group, Inc. Greg Gin/Doug Sherk (646) 445-48

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com EVC Group, Inc. Greg Gin/Doug Sherk (646) 445-4801; (415) 652-9100 ggin@evcgroup.com ; dsherk@evcgroup.com EVC Group, Inc. Chris G

Oct 20, 2011

SUMMARY OF THE STOCK AND INCENTIVE AWARD PLAN an24485839-ex99_1.htm Exhbit 99.1 Summary Description of the AngioDynamics, Inc. 2004 Stock and Incentive Award Plan (as amended) The following is a summary of the principal

Aug 16, 2011

AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com EVC Group, Inc. Doug Sherk/ Greg Gin (415) 568-4

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com EVC Group, Inc. Doug Sherk/ Greg Gin (415) 568-4887; (646) 445-4801 dsherk@evcgroup.com ; ggin@evcgroup.com EVC Group, Inc. Steve

Jun 13, 2011

AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com EVC Group, Inc. Doug Sherk (415) 896-6820 dsherk

Company Contact: Investor Relations Contacts: Media Contact: AngioDynamics, Inc. D. Joseph Gersuk, CFO (800) 772-6446 x1608 jgersuk@AngioDynamics.com EVC Group, Inc. Doug Sherk (415) 896-6820 dsherk@evcgroup.com Greg Gin (646) 445-4801 ggin@evcgroup.com EVC Group, Inc. Chris Gale

Jan 25, 2011